Nanoparticle immunoconjugates

US2020353096A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2020353096-A1
Application numberUS-201916720176-A
CountryUS
Kind codeA1
Filing dateDec 19, 2019
Priority dateApr 7, 2015
Publication dateNov 12, 2020
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attached thereto.

First claim

Opening claim text (preview).

1 - 44 . (canceled) 45 . An immunoconjugate comprising: a nanoparticle coated with an organic polymer; an antibody fragment conjugated to the organic polymer-coated nanoparticle, a therapeutic agent conjugated to the organic polymer-coated nanoparticle through a linker, wherein the nanoparticle has a diameter no greater than 20 nanometers, wherein the nanoparticle comprises a silica-based core and a silica shell surrounding at least a portion of the core, wherein the antibody fragment is a single chain variable fragment (scFv). 46 . The immunoconjugate of claim 45 , wherein the linker is a cleavable linker. 47 . The immunoconjugate of claim 46 , wherein the cleavable linker is selected from a group consisting of peptide, hydrazine and disulfide linkers. 48 . The immunoconjugate of claim 45 , wherein the linker is a peptide linker. 49 . The immunoconjugate of claim 45 , wherein the linker is a peptide linker that is cleaved by lysosomal proteases. 50 . The immunoconjugate of claim 49 , wherein the lysosomal protease is cathepsin-B. 51 . The immunoconjugate of claim 45 , wherein the linker is a dipeptide linker. 52 . The immunoconjugate of claim 51 , wherein the dipeptide linker is a valine-citrulline linker. 53 . The immunoconjugate of claim 45 , wherein the antibody fragment is from about 25 kDa to about 30 kDa. 54 . The immunoconjugate of claim 45 , wherein the nanoparticle comprises a fluorescent compound within the core. 55 . The immunoconjugate of claim 45 , wherein the nanoparticle has from one to ten antibody fragments attached thereto. 56 . The immunoconjugate of claim 45 , wherein the nanoparticle has a diameter no greater than 15 nanometers. 57 . The immunoconjugate of claim 45 , wherein the nanoparticle has a diameter in a range from 1 nm to 20 nm. 58 . The immunoconjugate of claim 45 , wherein the antibody fragment comprises anti-VEGF-A. 59 . The immunoconjugate of claim 45 , wherein the immunoconjugate comprises one or more imaging agents. 60 . The immunoconjugate of claim 59 , wherein the one or more imaging agents comprise a PET tracer. 61 . The immunoconjugate of claim 59 , wherein the one or more imaging agents comprise a fluorophore. 62 . The immunoconjugate of claim 4 , wherein the therapeutic agent comprises a chemotherapy drug. 63 . The immunoconjugate of claim 45 , wherein the therapeutic agent comprises a radioisotope. 64 . The immunoconjugate of claim 63 , wherein the radioisotope is a member selected from the group consisting of 99m Tc, 111 In, 64 Cu, 67 Ga, 186 Re, 188 Re, 153 Sm, 177 Lu, 67 Cu, 123 I, 124 I, 125 I, 11 C, 1 3N, 15 O, 18 F, 186 Re, 188 Re, 153 Sm, 166 Ho, 177 Lu, 149 Pm, 90 Y, 213 Bi, 103 Pd, 109 Pd, 159 Gd, 140 La, 198 Au, 199 Au, 169 Yb, 175 Yb, 165 Dy, 166 Dy, 67 Cu, 105 Rh, 111 Ag, 89 Zr, 225 Ac, and 192 Ir.

Assignees

Inventors

Classifications

  • Fab or Fab' · CPC title

  • Single chain antibody (scFv) · CPC title

  • the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb · CPC title

  • Antineoplastic agents · CPC title

  • A61K47/52Primary

    the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2020353096A1 cover?
Disclosed herein are nanoparticle immunoconjugates useful for therapeutics and/or diagnostics. The immunoconjugates have diameter (e.g., average diameter) no greater than 20 nanometers (e.g., as measured by dynamic light scattering (DLS) in aqueous solution, e.g., saline solution). In certain embodiments, the conjugates are silica-based nanoparticles with single chain antibody fragments attache…
Who is the assignee on this patent?
Memorial Sloan Kettering Cancer Center, Univ Cornell, Univ Missouri
What technology area does this patent fall under?
Primary CPC classification A61K47/6923. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Thu Nov 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).